Cancer News and Research

Latest Cancer News and Research

New UH Seidman Cancer Center center to offer latest treatments and technology

New UH Seidman Cancer Center center to offer latest treatments and technology

Global gene therapy market to reach $300 million by 2015

Global gene therapy market to reach $300 million by 2015

New blog aims to help dispel many myths behind cervical smear test

New blog aims to help dispel many myths behind cervical smear test

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Estrogen therapy improves low bone density in teenage girls with anorexia nervosa

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

Androgen deprivation therapy may increase risk of diabetes in men with prostate cancer

NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

Additional radiation treatment shows promise for breast cancer surgery patients

Additional radiation treatment shows promise for breast cancer surgery patients

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Researcher finds thyroid cancer gene inhibits spread of malignant cells

Researcher finds thyroid cancer gene inhibits spread of malignant cells

Study suggests strong link between dying from breast cancer and being obese

Study suggests strong link between dying from breast cancer and being obese

Anti-Mullerian hormone test can indicate reproductive function in young women with cancer

Anti-Mullerian hormone test can indicate reproductive function in young women with cancer

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

New targeted therapy may halt tumor growth in men with advanced prostate cancer

New targeted therapy may halt tumor growth in men with advanced prostate cancer

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Super microscopes help scientists identify exact molecular 'switch' that spurs T-cells into action

Super microscopes help scientists identify exact molecular 'switch' that spurs T-cells into action

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.